Among those with a high TLR2 expression, patients with a CD3–CD8 tumor–stroma index of 4 s had a five-year DSS of 82.2% (95% CI 70.2–94.2) compared to 51.8% (95% CI 40.6–63.0; p < 0.001, log-rank test; Fig 3b) among patients with an index of 0. The gene discussed is CD8A; the disease is neoplasm.